These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Streptodecase-2 in the treatment of acute myocardial infarct, unstable stenocardia, thromboembolism and thrombosis].
    Author: Butorov VN, Repinskaia NP, Demidova AV, Sysoeva NA, Kirichenko AA.
    Journal: Ter Arkh; 1990; 62(8):21-6. PubMed ID: 2274864.
    Abstract:
    Eleven patients underwent thrombolytic therapy with streptodekase-1 and 19 with streptodekase-2. Of these, 11 patients suffered acute myocardial infarction, 10 had unstable angina pectoris, 6 thromboembolism of the pulmonary artery, 2 thromboembolism of the peripheral arteries and 1 thrombosis of the femoral vein. Administration of streptodekase-2 brought about an increase of the total blood fibrinolytic activity (the fibrinolysis time dropped from 248.8 +/- 82.1 to 137.5 +/- 42.5 min after 12 h), plasmin activation (from 0.00 +/- 0.00 to 23.5 +/- 7.5 mg after 24 h), reduction of the plasminogen content (from 94.0 +/- 2.5 to 46.8 +/- 5.3% after 12 h). The parameters of the coagulation hemostasis did not undergo any appreciable changes. Fibrinolysis activation following streptodekase-2 administration was unchanged within the first 48 hours. No material differences were identified in fibrinolysis activation in patients given streptodekase-2 and streptodekase-1. Administration of streptodekase-2 was found to exert a marked beneficial clinical effect on acute myocardial infarction, unstable angina pectoris, thromboembolism of the pulmonary and peripheral arteries.
    [Abstract] [Full Text] [Related] [New Search]